Print Page  Close Window
Receive E-mail AlertsE-mail Alerts
Keyword Search
2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
02/11/16Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Period Progress
– Advanced Pipeline of Eight Clinical Stage Programs in 2015, with Ten or More Major Clinical Data Readouts, Start of Fitusiran Phase 3 Trials, and Three New IND Filings Planned in 2016 – – Completed Enrollment in Patisiran Phase 3 APOLLO Trial, Positioning the Company for First Filing for Regulatory Approval in 2017 – – Maintained Strong Balance Sheet with $1.28 Billion in Cash and Expects to End 2016 with Greater than $850 Million in Ca... 
Printer Friendly Version
02/04/16Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2015 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 4, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2015 on Thursday, February 11, 2016, after the U.S. financial markets close. Management will provide an update on the company, discuss fourth quarter and year-end 2015 results, and discuss expectations ... 
Printer Friendly Version
02/01/16Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
– Company Remains on Track to File New Drug Application in 2017 without Interim Analysis for Efficacy – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it has completed enrollment – with well over 200 patients accrued – in its APOLLO Phase 3 study with patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) for ... 
Printer Friendly Version
02/01/16Alnylam to Webcast Presentations at Upcoming February Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 3:00 pm ET as well as the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 1:25 pm ET, both at the Waldorf Astoria in New Yor... 
Printer Friendly Version
01/11/16Alnylam Outlines 2016 Goals for RNAi Therapeutics Pipeline
– Company Plans to Advance Multiple Phase 3 Programs, Including Start of Two Fitusiran Phase 3 Studies, and Expects Ten or More Major Clinical Data Readouts and Three New IND Filings – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 11, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today its pipeline goals for 2016 across its Genetic Medicine, Cardio-Metabolic Disease, and Hepatic Infectious Dise... 
Printer Friendly Version
01/04/16Alnylam to Webcast Presentation at 34th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2016-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2016 at 10:00 am PT (1:00 pm ET) at The Westin St. Francis in San Francisco. This presentation will include a review of the company’s goals and guidance. In addition, the compan... 
Printer Friendly Version

This part of our website contains archived information which should not be considered current and may no longer be accurate.